On the other hand, incorporating PRS into BC risk estimation may help identify 30% of CHEK2 and nearly half of ATM carriers below the 20% lifetime risk threshold, suggesting the addition of PRS may prevent over screening and enable more personalized risk management approaches [175]. The gene discussed is ATM; the disease is breast cancer.